---
title: "Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Indication questions"
description: "Indication questions on Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names and Testing. Questions: What is DATROWAY (datopotamab deruxtecan) approved to treat in HR-positive, HER2-negative breast cancer? What is the generic name of DATROWAY? Does DATROWAY require Trop-2 testing? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Indication questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Datroway](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true)

## Indication

<a id="datroway-breast-cancer-indication"></a>

### What is DATROWAY (datopotamab deruxtecan) approved to treat in HR-positive, HER2-negative breast cancer?

> “DATROWAY<sup>®</sup> (datopotamab deruxtecan-dlnk) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH−) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.”

Source: [DATROWAY: TROPION-Breast01 Trial, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/study-design#:~:text=%28datopotamab%20deruxtecan%2Ddlnk%29%20is%20a%20Trop%2D2%2Ddirected,for%20unresectable%20or%20metastatic%20disease.)

## Drug names

<a id="datroway-generic-name"></a>

### What is the generic name of DATROWAY?

> “DATROWAY<sup>®</sup> (datopotamab deruxtecan-dlnk) for injection, for 
> intravenous use”

Source: [DATROWAY: Prescribing information, page 1, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=1)

## Testing

<a id="datroway-trop2-testing"></a>

### Does DATROWAY require Trop-2 testing?

> “Trop-2 testing not required for DATROWAY.<sup>1</sup>”

Source: [DATROWAY: TROPION-Breast01 Trial, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/study-design#:~:text=Trop%2D2%20testing%20not%20required%20for)

## Related pages
- [Medical information: Datroway (datopotamab deruxtecan-dlnk): HR-positive HER2-negative breast cancer](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer)
- [Pharmacology](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/access-and-coverage)
